Evogene Ltd 6-K, filed May 11, 2023
Evogene Ltd. (EVGN)
6-K
2023-05-11
For: 2023-05-11
View Original
Added on
April 05, 2026
About this 6-K
Evogene Ltd filed this 6-K on May 11, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2023
Commission File Number 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of
the Company approved all the proposals brought before the annual general meeting of shareholders held on May 11, 2023 (following a one-week adjournment from the original meeting date) (the “Meeting”), by
the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign
Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on March 30, 2023, and sent in connection with the Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration
statements on Form F-3 (SEC File No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: May 11, 2023 |
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer |
|||
3